Anna Halpern, MD
Dr. Anna. B. Halpern is an Associate Professor in the Division of Hematology & Oncology at the University of Washington and an Assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center. Her clinical focus is on myelodysplastic syndromes, myeloproliferative neoplasms and acute myeloid leukemia. She also does clinical and outcomes research in myeloid malignancies evaluating novel care strategies and therapeutic approaches.
Dr. Halpern completed undergraduate and medical school at Brown University in 2009, residency in Internal Medicine at the University of Chicago in 2013, and fellowship in Hematology-Oncology at the Fred Hutchinson Cancer Research Center/ University of Washington in 2017.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:BayerTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:08/31/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Jazz pharmaceuticalsTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:10/22/2022
-
Attribution:SelfType of financial relationship:OtherIneligible company:Imago BiosciencesTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:08/31/2026
-
Attribution:SelfType of financial relationship:OtherIneligible company:Gilead SciencesTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Karyopharm TherapeuticsTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:10/31/2026
-
Attribution:SelfType of financial relationship:OtherIneligible company:Incytes PharmaceuticalsTopic:research contractDate added:05/27/2022Date updated:10/20/2023Relationship end date:12/31/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Agios PharmaceuticalsTopic:ConsultingDate added:05/27/2022Date updated:10/20/2023Relationship end date:07/01/2020
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbvieTopic:consultingDate added:05/27/2022Date updated:10/20/2023Relationship end date:06/01/2021
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Notable LabsTopic:consultingDate added:05/27/2022Date updated:10/20/2023Relationship end date:04/06/2022